Comparative immunity update
October 19, 2021
296,668
7,757
4,135
4.01%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Campbell Episodes Around October 19, 2021
See what was published immediately before and after this episode.
27:30Now PlayingComparative immunity update
YouTube Description
as posted by the channelHigh infection rates in UK, going down in US
Lower functional immunity in our population than most other
Western European countries
Early vaccine roll out
AstraZeneca protects slightly less well than Pfizer against infection and transmission, particularly delta variant
Slightly lower overall vaccination coverage, particularly vaccinating teenagers
Fewer social restrictions
High rates of testing
UK, ONS
Two vaccine doses give similar protection as previous infection
Two doses of either Pfizer-BioNTech or Oxford-AstraZeneca
Provided a similar level of protection as having had a previous natural infection of coronavirus
During delta variant times
Vaccination reduced the risk of testing positive,
both when the alpha variant was dominant in the UK (1 December 2020 to 16 May 2021)
and when the delta variant was dominant (17 May to 14 August 2021)
Two doses of Pfizer-BioNTech
Reduced the risk of testing positive by 73% in the delta period
Two doses of Oxford-AstraZeneca
Reduced the risk of testing positive by 62% in the delta period
Two vaccination doses, more effective than one at preventing symptomatic infection in both periods.
Three weeks after vaccination
Two doses always more protective than one
(75% v 58%)
Inconsistent with covid symptom study
Two doses of the Pfizer
87% protection against infection
Two doses of the AstraZeneca
71% protection against infection
Natural infection alone
Only gave 65% protection against catching it again
Israeli data consistent with ONS but inconsistent with covid symptom study
Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel
Vaccination was highly effective
Estimated efficacy for documented infection of 92·8%
Hospitalization 94·2%
Severe illness 94·4%
Death 93·7%
Protection from prior SARS-CoV-2 infection
Estimated efficacy for documented infection of 94·8%
Hospitalization 94·1%
Severe illness 96·4%
All deaths registered in the week to 8 October
COVID-19 deaths fall in England, Northern Ireland and Scotland
Up in Wales
Total UK deaths in the week, 12,490
14.7% above the average in 2015 to 2019
820 involved the coronavirus (COVID-19)
154 fewer than the previous week
Deaths involving COVID-19, 1 in 15 deaths (6.6%).
UK total deaths include non-residents.
1 million people in UK countries had COVID-19 in the latest week
1.63% in England (1 in 60 people)
One in 70 people the week before
2.18% in Wales (1 in 45 people)
One in 55 people the week before
0.82% in Northern Ireland (1 in 120 people)
One in 130 people the week before
1.26% in Scotland (1 in 80 people)
One in 60 people the week before
Greg and Peter
Hello John, Just to let you know that one of my posts referring to your video on aspiration has been pulled from LinkedIn. This is the first time that one of my posts has been pulled and I have put out some pretty controversial posts on other subjects.
Feedback from vaccine manufacturers
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.